Medicare UDS Frequency Limits: G0480–G0483 SUD Billing Guide

We see the same pattern across nearly every SUD practice we onboard at Revenant Care Group: providers are billing urine drug screens (UDS) on clinical reflex alone, documenting the medical necessity, running the test, and assuming the claim will pay. What they are not tracking is Medicare’s frequency edits for G0480, G0481, G0482, and G0483, and that blind spot is quietly generating denial rates of 20 to 35 percent on UDS lines at practices averaging 80 to 120 Medicare patients per month.

This post is for the CFO or RCM director who already knows the G-codes exist but needs the exact frequency rules, the modifier strategy, and the documentation framework that makes auditors comfortable. We are going to be specific, because vague guidance is why this problem persists.

What G0480 Through G0483 Actually Cover in 2026

These four G-codes represent presumptive and definitive drug testing under Medicare’s laboratory fee schedule. The key distinctions matter for both billing and frequency analysis:

• G0480: Definitive drug test, 1 to 7 drug classes. The 2026 Medicare national non-facility rate is approximately $97.93.
• G0481: Definitive drug test, 8 to 14 drug classes. Approximately $174.20 reimbursement.
• G0482: Definitive drug test, 15 to 21 drug classes. Approximately $248.11.
• G0483: Definitive drug test, 22 or more drug classes. Approximately $319.40.

Presumptive screening (G0477 through G0479) feeds the confirmation workflow, but the revenue concentration is in G0480 through G0483. A practice billing G0483 twice weekly per patient is almost certainly over the limit and flagging automated edits at the MAC level before a human reviewer ever sees it.

The Actual Medicare Frequency Limits You Need to Know

Medicare does not publish a single universal frequency limit for UDS in a neat LCD table. The operative guidance comes from Local Coverage Determinations, most critically Novitas LCD L36318, CGS LCD L36166, and Palmetto GBA LCD L36382. Each MAC controls the geographic territory where your practice bills. That said, the consensus benchmark that we work from across all MAC jurisdictions in 2026 is this:

• Presumptive screening: Up to 8 times per rolling 12 months per beneficiary without additional documentation burden.
• Definitive confirmation (G0480 to G0483): Typically supported at 8 to 12 times per 12-month period for high-risk SUD patients on controlled substances or medication-assisted treatment (MAT) such as buprenorphine or methadone.
• Higher frequency: Greater than 12 definitive tests per year is defensible only when clinical documentation explicitly ties each test to a specific clinical decision, such as dose adjustment, diversion concern, or a new controlled substance introduction.

Where practices fail: they bill G0483 at every visit, often weekly, because the EHR order set defaults to a 22-plus panel. At 48 tests per year per patient, even a 20-patient Medicare census generates roughly $306,624 in billed charges. If 35 percent of those are denied on frequency grounds, that is $107,318 sitting in write-offs that should be collectable with proper pre-authorization documentation and order justification built into your workflow.

The Modifier and POS Mistakes Compounding Your Denials

Frequency denials rarely travel alone. When we pull AR reports from a new SUD client, we almost always find frequency issues stacked with two other billing errors that the provider did not connect to each other.

Place of Service errors: G0480 through G0483 billed with POS 11 (office) when the test is actually processed at a reference laboratory creates a split-billing issue. If your practice collects the specimen but sends it to a CLIA-certified reference lab, the lab bills the G-code under POS 81. You bill only the specimen collection under the appropriate collection code. Billing the definitive code under POS 11 when you do not own the analyzer is a false claim exposure, not merely a denial risk.

Modifier misuse: Modifier 91 (repeat clinical diagnostic laboratory test) is appropriate when the same test is repeated on the same day for a separate clinical reason. We see practices incorrectly applying modifier 59 to UDS lines to bypass edits. Medicare’s NCCI edits are not resolved by modifier 59 in the same way a procedure bundling conflict is. Using 59 to push through a frequency-denied G-code does not correct the underlying documentation gap and increases audit exposure.

For a deeper look at why most SUD practices are also systematically under-coding their drug screen panels and leaving 4 to 5 times the revenue per test unrealized, read our detailed breakdown at G0480 to G0483 Drug Screen Coding: Why Most SUD Practices Are Under-Coding.

Building a Frequency-Defensible Documentation Template

The single most effective operational change we implement at practices with UDS denial rates above 15 percent is a standing order protocol tied to a frequency tracker in the practice management system. Here is what the documentation structure needs to contain to survive a MAC review or a RAC audit:

• Clinical indication per test date: Not a generic “monitoring compliance with MAT.” The note needs to state the specific drug classes being tested and why those classes are clinically relevant on that date.
• Treatment phase notation: Early stabilization (months 1 through 3 of MAT) justifies higher frequency than maintenance phase. Your documentation needs to reflect phase-appropriate rationale.
• Decision linkage: Every test result should connect to a documented clinical decision in the same note or the subsequent visit note. If the test result produces no documented action, it reads as reflexive ordering to a reviewer.
• Panel size justification: If you are billing G0482 or G0483, your order and the confirmatory result report need to show that 15 or 22-plus classes were ordered based on the patient’s specific substance history and current prescriptions, not because it is the default panel.

What Recovery Looks Like at Different Practice Sizes

At a practice billing Medicare UDS for 20 patients per month with an average G0482 rate, assuming approximately $248 per test and 24 annual tests per patient at current frequency patterns, gross billed UDS revenue is roughly $119,040 annually. A 25 percent denial rate on frequency grounds means $29,760 in annual write-offs on that single code family alone.

For a practice with 60 Medicare SUD patients in the same scenario, the write-off exposure climbs to approximately $89,280 per year. In our experience working with approximately 50 behavioral health and SUD practices, practices in the 50 to 100 Medicare patient range consistently recover between 60 and 75 percent of their denied UDS revenue when they implement structured frequency tracking, correct their documentation protocols, and file properly supported appeals within the 180-day reopening window.

That recovery is not theoretical. It is the result of pulling the denial EOBs, mapping denial reason codes (most commonly CARC 119 and CARC 4 for frequency and medical necessity), and submitting appeal packets that include the clinical documentation structure described in the previous section. It is also worth noting that parity law requirements can create additional leverage in commercial payer disputes over UDS frequency restrictions, a strategy we cover in depth at Mental Health Parity Act Appeals: How Behavioral Health Practices Are Leaving Money on the Table.

The Compliance Risk You Cannot Afford to Ignore

Frequency denials that are routinely written off without appeal do not just cost revenue. They create a claims pattern that flags your practice for prepayment review or a Targeted Probe and Educate (TPE) audit. Once a MAC places your NPI under TPE, 100 percent of your UDS claims in the review period are manually reviewed, which means your entire UDS revenue stream is at risk for 60 to 90 days while the audit is conducted. The compliance cost of failing to manage frequency documentation is almost always larger than the AR impact of the original denials.

Review your MAC’s current LCD for definitive drug testing before your next billing cycle. If your practice is in a Novitas or CGS jurisdiction and you have not reviewed LCD L36318 or L36166 since 2024, the policy language has been refined and your standing orders may no longer align with current coverage criteria.

Start Recovering Your UDS Revenue Now

If your UDS denial rate on G0480 through G0483 is above 10 percent, or if you cannot tell us your denial rate by code right now, that is the problem we fix first. At Revenant Care Group, we offer a free 30-day denial audit that maps every G-code denial by reason code, payer, and patient volume so you know exactly where the revenue is and what it takes to recover it. Schedule your free audit directly at our booking calendar and we will show you what your UDS claims are actually worth.